Key facts
as of Sep 2026- Notable investors include General Inception, LifeX Ventures, Pennsylvania State University.
- 5 institutional filers report fund marks on Illuminate Therapeutics across 15 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Illuminate Therapeutics
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Illuminate Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
5 filers · latest Jun 20265 SEC-registered funds reported 15 fair-value marks on Illuminate Therapeutics between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Illuminate Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Illuminate Therapeutics
Developer of a drug delivery system designed to treat oncology and autoimmune diseases. The company uses light to target therapeutic agents to a specific disease area in the body, enabling healthcare providers to use more potent chemicals safely to target cancer cells.
- Sector
- Healthcare
- HQ
- PA
- Ownership
- Privately Held (backing)